PCN44 Cost-Effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable Stage III NSCLC Patients in the US: An Update Based on 4-Year Survival Data

Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.136
https://www.valueinhealthjournal.com/article/S1098-3015(21)00353-3/fulltext
Title : PCN44 Cost-Effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable Stage III NSCLC Patients in the US: An Update Based on 4-Year Survival Data
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00353-3&doi=10.1016/j.jval.2021.04.136
First page :
Section Title :
Open access? : No
Section Order : 10712
Categories :
Tags :
Regions :
ViH Article Tags :